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ABSTRACT 
Introduction: Bisphosphonates (BF) are inhibitors of 
reabsorption bone and are indicated for the treatment of 
Osteoporosis, Bone Metastasis, Multiple Myelomas and 
Paget's Disease. They are pyrophosphate analogs, which 
have high affinity for bone tissue inhibiting the action of 
osteoclasts. Although it has benefits for patients with of 
such diseases by assisting, for example, in the pain control 
prolonged use may lead to osteonecrosis of the jaws. 
Objectives: This article aims to review themedical 
literature on the use of bisphosbonates and dental 
surgeries. 
Materials and Methods: The indexed articles google 
academico and PubMed were scanned and the articles 
with the highest impact factor were selected. 
Results: We found 350 articles and selected 20 with the 
highest impact factor. 
Conclusion: Bisphosphonates are substances that can 
cause oteonecrosis in patients undergoing invasive dental 
treatments. 
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Osteonecrosis of the maxilaries associated with 
use of biphosphonate 
  
ABSTRACT 
Introduction: Bisphosphonates (BF) are inhibitors of reabsorption bone and are 
indicated for the treatment of Osteoporosis, Bone Metastasis, Multiple Myelomas 
and Paget's Disease. They are pyrophosphate analogs, which have high affinity 
for bone tissue inhibiting the action of osteoclasts. Although it has benefits for 
patients with of such diseases by assisting, for example, in the pain control 
prolonged use may lead to osteonecrosis of the jaws. 
Objectives: This article aims to review themedical literature on the use of  
bisphosbonates and dental surgeries. 
Materials and Methods: The indexed articles google acadêmico and PubMed 
were scanned and the articles with the highest impact factor were selected. 
Results: We found 350 articles and selected 20 with the highest impact factor. 
Conclusion: Bisphosphonates are substances that can cause oteonecrosis in 
patients undergoing invasive dental treatments. 
Key words: Osteonecrosis, bisphosphonate, necrosis of the jaws 
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INTRODUCTION 
Bisphosphonates in the 1960s were presented as a therapeutic drug for 
diseases with impaired bone, but are currently prescribed primarily for the 
treatment of osteoporosis 3.  
This medicine has the ability to bind to bone and inhibit the function of 
osteoclasts because they are analogous of pyrosphosphates. Not being 
metabolized by the organism the concentration at the bone level and for months 
/ years. Such drugs decrease bone turnover which inhibit bone resorption at 
tissue level. In the cells the bisphosphonates have action on the osteoclástos, It 
may be through inhibition of recruitment of osteoclasts, by inhibiting the lifespan 
of the osteoclasts and their activity on the bone surface. In relation to the 
molecules, they bind to the receptor of surface of the osteoclasts or in an 
intracellular enzyme 3. 
 They can be found in two presentations, for orally indicated for the 
treatment of Osteoporosis, Osteopenia and Paget's disease and endovenous 
route used in Oncological diseases. Adverse reactions are: asthenia, anemia, 
dyspnoea, changes in creatinine levels, gastrointestinal symptoms and 
esophageal ulcers 13. 
 He reports that treatment consists of eliminating pain and prevent 
recurrence of infections and symptoms, through of antibiotic therapy, when signs 
of infection are gifts, and topical antimicrobial agents. Exist situations in which the 
associated hyperbaric therapy the surgery and the interruption or substitution of 
the administration of the drug for six months, being three before and three months 
after the procedure are indicated 2. 
 The objective of this study is to report the possible complications that can 
occur in a procedure in patients taking bisphosphonates on a long-term basis. 
 
METHODS 
To perform a literature review on case reports that refer to the etiology, 
characteristics and therapeutics of osteonecrosis associated with the use of 
bisphosphonate in database of Bireme, Scielo and Google Scholar. 
Articles, dissertations and theses were searched in Portuguese, English and 
Spanish indexed in computerized archives of the bases cited above. 
 
SYSTEMATIC REVIEW 
Bisphosphonates prevent cell characterization osteoclast percussive cells 
its action, inciting the cellular apoptosis, altering the cellular structure in the period 
that precedes this fact. There is a of cytoplasmic prominences responsible for the 
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deterioration of the organic matrix of tissue bone. In addition to such activities, 
antiangiogenic properties such as decreased number of blood vessels and 
endothelial responses to angiogenic hormones have been described 1. 
Treatment consists of eliminating pain complaints and prevent recurrence 
of infections and symptoms, through of antibiotic therapy, when signs of infection 
are gifts, and topical antimicrobial agents. Exist situations in which the associated 
hyperbaric therapy the surgery and the interruption or substitution of the 
administration of the drug for six months, being three before and three months 
after the procedure are indicated 2. 
The AOMS ranked in three the stages for the OMAB, first stage: bone 
necrosis with exposure without evidence of infection and symptoms, according to 
stage: necrosis with bone exposure, infection (pain, erythema with or without 
purulent drainage), third stage: bone necrosis with bone exposure, infection and 
possible pathological fractures, extra oral fistulas, osteolysis involving lower lip of 
the mandible. The treatment consists in the use of mouthwashes in the three 
stages, Antibiotic therapy accompanied by microbiological and analgesic culture 
for pain relief and debridement (second and third stages), third stage the 
debridement becomes more aggressive 3. 
In 2009, the AOMS classified the risk factors for ONMS, first category: drug-
related factors (potency and duration of second category: demographic and 
systemic risk factors (the Caucasian race has a greater predisposition about 9% 
per decade), third category: rich local factors (dentoalveolar surgery, local 
anatomy and concomitant oral diseases) fourth category: genetic risk factors and 
fifth category: factors preventive measures (evaluation of the oral health status 
before onset of therapy 4. 
The components of such drugs are stored in the bone matrix and can remain 
for years in the organism, resulting in the degeneration of capillaries, 
vascularization and are susceptible to fracture 5. 
The first publication of a case report on osteonecrosis in the mandible 
occurred in 2003 reported Max. The bone necrosis is irreversible, since the tissue 
bone and unable to undergo remodeling and for this reason he suffers necrosis 
6. 
Bisphosphonates are drugs indicated for the treatment of Osteoporosis, 
Bone Metastasis, Multiple Myelomas, Pagets Disease. The action of this drug 
results in increased bone mass and mineralization. Surgeries oral implants, 
dental implants, periodontal surgeries and maladaptive prostheses are risk 
factors 7. 
The absorption of the bisphosphonates is well 50% absorbed by the bone 
and the route of elimination are the kidneys. The Unified Health System (SUS) 
provides the bisphosphonates for treatment of Imperfect Osteogenesis obtaining 
favorable results regarding the reduction of bone fracture. Recently the 
Pamidronato was introduced in Fibrous Dysplasia not have a formalized protocol 
8. 
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These drugs may have side effects and result in osteonecrosis of the jaws 
being that for this has to have a relationship between type x dose x history of 
trauma x oral surgeries x infections 9. 
The efficacy of these drugs in relation to pain control (patients with clinical 
breast, prostate and lung and multiple myeloma0 and loss (osteonecrosis) has 
been proven through The jaws are more susceptible and osteonecrosis due to its 
location, the oral cavity, by the microbiota present 10. 
These drugs are synthetic analogous to pyrophosphate the duration of this 
medicinal product in the blood can be from thirty minutes to two hours but when 
incorporated into the bone it can remain for until a decade 11,16. 
The diagnosis is made according to the history and clinical examination of 
the patient. The clinical characteristics are/ the necrotic lesions that may not 
present symptoms for years, becoming symptomatic only When adjacent tissues 
present infection or inflammation, the with the CTX  exam 12,17. 
Bisphosphonates have benefits when prescribed for cancer treatment 
because it reduces bone pain and skeletal complications, AAOMS (AAmerican 
Association of Oral Maxillofacial Surgeons), osteonecrosis as bone tissue 
exposed in the maxillofacial region that remains for more than eight weeks, in 
patients with previous or current treatment with bisphosphonates, who do not 
present history and radiotherapy of head and neck 13,18. 
These medications are indicated to maintain the bone density in patients 
with neoplasms with bone involvement. Can some adverse effects such as fever, 
renal hypercalcemia, maxillary necrosis 14,19. 
The pathogenesis is still unknown and the most Acceptance is direct action 
on osteoclasts leading to reduction of bone remodeling and inhibition of the 
vascular endothelial growth. The clinical and varied aspect may present exposure 
of the necrotic bone with pain and radiographically diffuse bone sclerosis, 
presence of bone sequestration, mandibular oral fistula, diffuse radiolucent spot, 
in panoramic lesions osteolytic cells in vertical cortical wrapping, histologically 
show necrotic trabecular bone with surrounding vascular tissue covered by 
granulation tissue, positive culture examination for some species fungal 
infections other than Actyomyces Spe Streptococcus intermedia 15,20. 
 
CONCLUSION 
Further research must be carried out for a better understanding of the 
mechanism of action of bisphosphonates in the jaws with the purpose of 
proposing protocol for proper treatment and implantation of a dental protocol prior 
to therapy, since the tooth extractions, which is a risk factor for osteonecrosis, 
are common surgical procedures in underdeveloped countries with Brazil. 
Prevention of Osteonecrosis is still the best way to conduct this complication. The 
dentist surgeon should keep in touch with the patient's physician and inform the 
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importance of maintaining oral health as a means of preventing and reduce the 
risks of the disease.  
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